AU2018215466B2 - Small molecule antagonists of SUMO related modification of CRMP2 and uses thereof - Google Patents

Small molecule antagonists of SUMO related modification of CRMP2 and uses thereof Download PDF

Info

Publication number
AU2018215466B2
AU2018215466B2 AU2018215466A AU2018215466A AU2018215466B2 AU 2018215466 B2 AU2018215466 B2 AU 2018215466B2 AU 2018215466 A AU2018215466 A AU 2018215466A AU 2018215466 A AU2018215466 A AU 2018215466A AU 2018215466 B2 AU2018215466 B2 AU 2018215466B2
Authority
AU
Australia
Prior art keywords
benzo
piperidin
imidazol
methanone
fluorobenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018215466A
Other languages
English (en)
Other versions
AU2018215466A1 (en
Inventor
Reena CHAWLA
Vijay Gokhale
May KHANNA
Rajesh Khanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Original Assignee
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona filed Critical University of Arizona
Publication of AU2018215466A1 publication Critical patent/AU2018215466A1/en
Application granted granted Critical
Publication of AU2018215466B2 publication Critical patent/AU2018215466B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018215466A 2017-02-03 2018-02-02 Small molecule antagonists of SUMO related modification of CRMP2 and uses thereof Active AU2018215466B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762454475P 2017-02-03 2017-02-03
US62/454,475 2017-02-03
US201762506298P 2017-05-15 2017-05-15
US62/506,298 2017-05-15
PCT/US2018/016687 WO2018144900A1 (en) 2017-02-03 2018-02-02 Small molecule antagonists of sumo related modification of crmp2 and uses thereof

Publications (2)

Publication Number Publication Date
AU2018215466A1 AU2018215466A1 (en) 2019-08-22
AU2018215466B2 true AU2018215466B2 (en) 2022-03-10

Family

ID=63041159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018215466A Active AU2018215466B2 (en) 2017-02-03 2018-02-02 Small molecule antagonists of SUMO related modification of CRMP2 and uses thereof

Country Status (7)

Country Link
US (1) US11208397B2 (https=)
EP (1) EP3576734A4 (https=)
JP (1) JP7092776B2 (https=)
CN (1) CN110381941A (https=)
AU (1) AU2018215466B2 (https=)
CA (1) CA3052195A1 (https=)
WO (1) WO2018144900A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025129167A1 (en) * 2023-12-15 2025-06-19 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Inhibitors of the surface expression of the voltage-gated sodium ion channel 1.7 (nav1.7) and their therapeutic uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134920A1 (en) * 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
WO2017062804A1 (en) * 2015-10-07 2017-04-13 The Arizona Board Of Regents On Behalf Of The University Of Arizona Crmp2 sumoylation inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
JP2003512372A (ja) * 1999-10-18 2003-04-02 スミスクライン ビーチャム パブリック リミテッド カンパニー テトラヒドロベンゾインドロン誘導体、それらの製造および５−ｈｔ７受容体アンタゴニストとしてのそれらの使用
EP2240464A4 (en) * 2008-02-12 2011-09-14 Yuhan Corp PROCESS FOR THE PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE PRODUCTS
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
CN102627631B (zh) * 2012-03-31 2013-07-24 中国药科大学 苯并杂环类化合物、其制备方法及其医药用途
US9828348B2 (en) * 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
JP2018052817A (ja) * 2015-01-21 2018-04-05 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体およびその医薬用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015134920A1 (en) * 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
WO2017062804A1 (en) * 2015-10-07 2017-04-13 The Arizona Board Of Regents On Behalf Of The University Of Arizona Crmp2 sumoylation inhibitors and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1389137-38-5; STN Entry Date: 12 August 2012; [4-(1H-Benzimidazol-2-yl)-1-piperidinyl](tetrahydro-2H-pyran-4-yl)methanone *
CAS Registry Number 1390430-30-4; STN Entry Date: 13 August 2012; [4-(1H-Benzimidazol-2-yl)-1-piperidinyl][4-(cyclopropylmethoxy)phenyl]methanone *
CAS Registry Number 1420816-71-2 ; STN Entry Date 14 February 2013; 1,1-Dimethylethyl 4-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-1-piperidinecarboxylate *
CAS Registry Number 933704-38-2; STN Entry Date 30 April 2007; 2-(4-Piperidinyl)-1-[(tetrahydro-2-furanyl)methyl]-1H-benzimidazole *
CAS Registry Number: 1368721-60-1; STN Entry Date: 15 April 2012; 1-(2-Methoxyethyl)-2-(4-piperidinyl)-1H-benzimidazole *
CAS Registry Number: 836691-50-0; STN Entry Date: 24 February 2005; [4-(1H-Benzimidazol-2-yl)-1-piperidinyl]cyclopropylmethanone *

Also Published As

Publication number Publication date
EP3576734A4 (en) 2020-12-09
EP3576734A1 (en) 2019-12-11
CA3052195A1 (en) 2018-08-09
CN110381941A (zh) 2019-10-25
AU2018215466A1 (en) 2019-08-22
WO2018144900A1 (en) 2018-08-09
JP7092776B2 (ja) 2022-06-28
US20200277271A1 (en) 2020-09-03
JP2020505434A (ja) 2020-02-20
US11208397B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
US8546417B2 (en) Fused and spirocycle compounds and the use thereof
CN114085212A (zh) 异吲哚啉类化合物、其制备方法、药物组合物及用途
AU2009308769B2 (en) Filamin A-binding anti-inflammatory analgesic
RS54998B1 (sr) Antagonisti c5ar
US6187782B1 (en) Morphinane derivatives and medicinal use thereof
RS56332B1 (sr) Antagonisti c5ar
JP2003516391A (ja) ムスカリン性レセプターアンタゴニスト活性を有するウレア化合物
BRPI0707408A2 (pt) compostos de amido e seu uso como produtos farmacêuticos
WO2013110134A1 (en) Heterocyclic compounds and methods for their use
AU2013202973A1 (en) Heterocyclic compounds and methods for their use
EP3848351B1 (en) Dopamine d3 receptor selective antagonists/partial agonists; method of making; and use thereof
CA2970854A1 (en) New benzimidazole derivatives as antihistamine agents
JP7783174B2 (ja) 四員環誘導体の調節剤、調製方法及びその利用
AU2018215466B2 (en) Small molecule antagonists of SUMO related modification of CRMP2 and uses thereof
EP4286384A1 (en) Aza-ergoline derivative and preparation method therefor and application thereof
JP7434265B2 (ja) アンドロゲン受容体結合分子およびその使用
CN114727993B (zh) 作为Kv1.3钾SHAKER通道阻断剂的芳基亚甲基杂环化合物
EP4238970A1 (en) Modulators of ackr3 and uses thereof
BR112015009243B1 (pt) Composto de amina cíclico fluorosubstituído, método para preparar um composto de amina cíclico fluorosubstituído, composição farmacêutica, inibidor de acetilcolinesterase e uso do composto de amina cíclico fluorosubstituído
KR20210069585A (ko) 국소 부착 키나아제 저해제로서 신규한 아다만탄 유도체
TW202448467A (zh) 靶記細胞狀態之技術
US11299476B2 (en) Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
RU2823231C1 (ru) Соединение-антагонист PD-L1
RU2813232C2 (ru) Соединение изоиндолин, способ получения, фармацевтическая композиция и их применение
AU2023228096A1 (en) Histamine h3 receptor antagonist and medical use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)